OSE Pharma SA (OSE) - Total Assets
Based on the latest financial reports, OSE Pharma SA (OSE) holds total assets worth €104.18 Million EUR (≈ $121.80 Million USD) as of June 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check OSE total capital reinvestment ratio to assess the company's total reinvestment commitment from operating cash flow.
OSE Pharma SA - Total Assets Trend (2012–2024)
This chart illustrates how OSE Pharma SA's total assets have evolved over time, based on quarterly financial data. Explore OSE strategic capital deployment ratio to see how much of total assets are deployed in long-term investments.
OSE Pharma SA - Asset Composition Analysis
Current Asset Composition (December 2024)
OSE Pharma SA's total assets of €104.18 Million consist of 56.4% current assets and 43.6% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €9.31 Million | 13.5% |
| Accounts Receivable | €4.14 Million | 3.3% |
| Inventory | €0.00 | 0.0% |
| Property, Plant & Equipment | €3.42 Million | 2.8% |
| Intangible Assets | €44.01 Million | 35.5% |
| Goodwill | €0.00 | 0.0% |
Asset Composition Trend (2012–2024)
This chart illustrates how OSE Pharma SA's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see OSE market cap overview.
Key Asset Composition Facts
- Current vs. Non-Current Assets: OSE Pharma SA's current assets represent 56.4% of total assets in 2024, a decrease from 90.1% in 2012.
- Cash Position: Cash and equivalents constituted 13.5% of total assets in 2024, down from 65.6% in 2012.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 35.0% of total assets, an increase from 0.0% in 2012.
- Asset Diversification: The largest asset category is intangible assets at 35.5% of total assets.
OSE Pharma SA Competitors by Total Assets
Key competitors of OSE Pharma SA based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Revolution Medicines Inc
NASDAQ:RVMD
|
USA | $2.25 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
Metsera, Inc. Common Stock
NASDAQ:MTSR
|
USA | $639.66 Million |
|
Hugel Inc
KQ:145020
|
Korea | ₩1.13 Trillion |
|
Bicara Therapeutics Inc. Common Stock
NASDAQ:BCAX
|
USA | $553.60 Million |
|
Sinopep-Allsino Biopharmaceutical Co. Ltd. A
SHG:688076
|
China | CN¥6.82 Billion |
|
Absci Corp
NASDAQ:ABSI
|
USA | $195.59 Million |
|
Shenzhen Weiguang Biological Products Co Ltd
SHE:002880
|
China | CN¥3.67 Billion |
OSE Pharma SA - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.87 | 4.93 | 2.32 |
| Quick Ratio | 2.87 | 4.79 | 2.32 |
| Cash Ratio | 0.74 | 1.49 | 1.60 |
| Working Capital | €36.23 Million | €68.40 Million | €18.94 Million |
OSE Pharma SA - Advanced Valuation Insights
This section examines the relationship between OSE Pharma SA's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.80 |
| Latest Market Cap to Assets Ratio | 0.71 |
| Asset Growth Rate (YoY) | 51.1% |
| Total Assets | €123.96 Million |
| Market Capitalization | $88.43 Million USD |
Valuation Analysis
Below Book Valuation: The market values OSE Pharma SA's assets below their book value (0.71x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: OSE Pharma SA's assets grew by 51.1% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for OSE Pharma SA (2012–2024)
The table below shows the annual total assets of OSE Pharma SA from 2012 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | €123.96 Million ≈ $144.92 Million |
+51.07% |
| 2023-12-31 | €82.05 Million ≈ $95.93 Million |
-10.49% |
| 2022-12-31 | €91.67 Million ≈ $107.17 Million |
-9.70% |
| 2021-12-31 | €101.52 Million ≈ $118.69 Million |
+4.83% |
| 2020-12-31 | €96.85 Million ≈ $113.22 Million |
+8.95% |
| 2019-12-31 | €88.89 Million ≈ $103.92 Million |
+15.59% |
| 2018-12-31 | €76.90 Million ≈ $89.91 Million |
-0.58% |
| 2017-12-31 | €77.35 Million ≈ $90.43 Million |
-13.62% |
| 2016-12-31 | €89.55 Million ≈ $104.69 Million |
+426.90% |
| 2015-12-31 | €17.00 Million ≈ $19.87 Million |
+758.33% |
| 2014-12-31 | €1.98 Million ≈ $2.31 Million |
+489.29% |
| 2013-12-31 | €336.00K ≈ $392.82K |
+19.15% |
| 2012-12-31 | €282.00K ≈ $329.69K |
-- |
About OSE Pharma SA
OSE Immunotherapeutics SA, a clinical-stage biotechnology company, develops immunotherapies in the areas of immune-oncology and immune-inflammation in France and internationally. Its products include Tedopi that is in Phase III clinical trial for the treatment of non-small cell lung cancer, as well as in Phase II clinical trial to pancreatic and ovarian cancer; OSE-279, which is in a Phase I/II c… Read more